Abstract
The goal of this study is to examine the relationship between healthcare expenditures and health capacity, and variability in COVID-19 case fatality rate between European countries. In particular, the purpose of the present study is to see whether statistical evidence supports the hypothesis that the reduction of COVID-19 fatality, between European countries, can be explained by leveraging health expenditures and if so to form some quantitative analyses and estimates of the relation between health expenditures and COVID-19 fatality rate between countries. The research is based on a sample of European countries and data from various sources, including Eurostat, World Bank, and OECD databases. Results suggest that countries with higher COVID-19 fatality rate in 2020 (when pandemic starts) in comparison to countries with lower COVID-19 fatality had (higher) +50.5% of fatality in 2020, +52.9% in 2022, lower health expenditure as % of GDP −5.5%, health expenditure per capita −34.5%, R&D expenditures in health −30.3%, lower reduction of COVID-19 fatality from 2022-2022 by −57.2 % vs 59.3% of the other group. Results also show a negative association between COVID-19 Fatality in 2022 and Health expenditure as a share of GDP 2020 (r=−0.42, p-value 0.05); COVID-19 Fatality in 2022 and Vaccinations in December 2021 (r=−0.75, p-value 0.01). Difference of COVID-19 Fatality 22-20 has also negative correlation coefficients given by r=−0.48 (p-value 0.05) with Health expenditure as a share of GDP of 2020 and by r=−0.52 (p-value 0.01) with vaccinations in December 2021. Partial correlation, controlling population over 65yo in 2020, confirms previous results. The contribution here expands the knowledge in these research topics by endeavoring to clarify how higher health expenditures improve the preparedness and resilience in crisis management of countries to face unforeseen epidemic or pandemic similar to COVID-19 in society.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declaration of competing interest. The authors declare that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
No funding was received for this study
Data Availability
All data produced in the present study are available upon reasonable request to the authors
